<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311762</url>
  </required_header>
  <id_info>
    <org_study_id>00000613</org_study_id>
    <nct_id>NCT04311762</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer</brief_title>
  <official_title>Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to identify the maximum tolerated dose of endobronchial
      ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple studies have demonstrated feasibility and safety of delivering cisplatin directly
      into lung tumors using endobronchial ultrasound guided-transbronchial needle injection
      (EBUS-TBNI). This technique relies on the use of a bronchoscope with an integrated ultrasound
      transducer allowing real-time visualization of, and delivery of cisplatin into, tumors lying
      in proximity to the central airways. Prior work has utilized this technique to treat loco
      regional recurrence in a previously radiated field. The goal of the current study is to
      identify the initial dose for intratumoral cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Lung Cancer Metastatic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)</description>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eastern Cooperative Oncology Group (ECOG) performance score 0-2 Patients will have known or
        suspected Stage IV, metastatic, non-small cell lung cancer (NSCLC) after multidisciplinary
        review.

        Exclusion Criteria:

        Use of an investigational agent in prior 30 days Pregnancy/lactation Treatment with IV
        cytotoxic chemotherapy within the past 30 days Prior (within the last 12 months) or ongoing
        radiation treatment to the study NSCLC Allergy to cisplatin or its derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Burns</last_name>
    <phone>(802) 656-8307</phone>
    <email>stephanie.burns@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Burns</last_name>
      <phone>802-656-8307</phone>
      <email>stephanie.burns@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>C. Matthew Kinsey MD, MPH</investigator_full_name>
    <investigator_title>Director, Interventional Pulmonary</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

